US Pharma MarketingQ&A: Novo Nordisk research chief discusses streamlined R&D, asset integration and role of AI
Novo Nordisk Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s…
Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early ...
Source: Endpoints News